NCT02446990

Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure

Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double-blind Placebo-controlled International Multicenter Study. Study Assessing the Morbi-mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 19,102 (actual)
• Sponsor: Institut de Recherches Internationales Servier · Academic / Other
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effect of ivabradine on cardiovascular events in patients with coronary artery disease.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Ivabradine	5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
DRUG	Placebo	Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.

Timeline

• Start date: 2009-09-01
• Primary completion: 2014-01-01
• Completion: 2014-01-01
• First posted: 2015-05-18
• Last updated: 2024-07-26
• Results posted: 2015-06-25

Locations

2 sites across 2 countries: Italy, United Kingdom